Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples